Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06138210Phase 1Recruiting

The Effect of GD-iExo-003 in Acute Ischemic Stroke

Role: collaborator

NCT06810869Early Phase 1Not Yet Recruiting

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo

Role: collaborator

NCT05969717Early Phase 1Unknown

Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis

Role: collaborator

NCT05886205Early Phase 1Unknown

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy

Role: collaborator

All 4 trials loaded